Table 3.
Pharmacokinetics of 3-hydroxyquinine following a single oral dose (600 mg) of quinine sulphate to 10 healthy subjects during two treatment phases: control (quinine alone) and TAO (quinine +TAO). Data are presented as mean ± s.d. (95% CI).
| Measure | Control phase | TAO phase |
|---|---|---|
| AUC(0,∞) (mg l−1 h) | 7.7 ± 3.1 (5.8–9.5) | 3.4 ± 2.2* (2.0–4.7) |
| Cmax (mg l−1) | 0.32 ± 0.11 (0.25–0.38) | 0.08 ± 0.03* (0.06–0.09) |
| tmax (h) | 3.2 ± 1.8 (2.0–4.3) | 9.4 ± 8.2 (4.3–14.5) |
| t½ (h) | 14.3 ± 2.6 (12.7–15.9) | 25.7 ± 11.7** (18.5–33.0) |
| fe,3-OH | 7.1 ± 1.6 (6.1–8.2) | 2.5 ± 1.2* (1.7–3.3) |
| CL3-OH (l h−1) | 0.69 ± 0.17 (0.59–0.80) | 0.13 ± 0.07* (0.09–0.17) |
AUC(0,∞), area under the plasma concentration-time curve from zero to infinite time; Cmax, peak concentration; tmax, time to reach Cmax; t½, terminal elimination half-life; fe,3-OH, fraction of the dose excreted in urine as 3-hydroxyquinine; CL3-OH, apparent formation clearance of 3-hydroxyquinine.
*
P < 0.001;
**
P < 0.01 (paired Student's t-test)